300683 海特生物
已收盘 07-24 15:00:00
资讯
新帖
简况
海特生物最新公告：注射用埃普奈明临床试验申请获受理
证券之星 · 07-24 16:54
海特生物最新公告：注射用埃普奈明临床试验申请获受理
海特生物：推进埃普奈明新产能扩建及新适应症拓展
证券之星 · 07-15
海特生物：推进埃普奈明新产能扩建及新适应症拓展
股市必读：海特生物(300683)股东户数1.77万户，较上期增加2.97%
证券之星 · 07-09
股市必读：海特生物(300683)股东户数1.77万户，较上期增加2.97%
海特生物：埃普奈明的新建设计产能为120万支
证券之星 · 07-08
海特生物：埃普奈明的新建设计产能为120万支
海特生物：截止6月30日，公司股东人数为17,691户
证券之星 · 07-08
海特生物：截止6月30日，公司股东人数为17,691户
股市必读：海特生物(300683)股东户数1.77万户，较上期增加2.97%
证券之星 · 07-07
股市必读：海特生物(300683)股东户数1.77万户，较上期增加2.97%
海特生物：截止6月30日，公司股东人数为17,691户
证券之星 · 07-06
海特生物：截止6月30日，公司股东人数为17,691户
海特生物（300683）披露将参加2026年湖北辖区投资者集体接待日暨2025年度业绩说明会，7月02日股价上涨0.11%
证券之星 · 07-02
海特生物（300683）披露将参加2026年湖北辖区投资者集体接待日暨2025年度业绩说明会，7月02日股价上涨0.11%
海特生物：注射用硫酸艾沙康唑是公司今年刚获批的产品
证券之星 · 06-25
海特生物：注射用硫酸艾沙康唑是公司今年刚获批的产品
海特生物(300683)6月18日股东户数1.72万户，较上期减少0.16%
证券之星 · 06-24
海特生物(300683)6月18日股东户数1.72万户，较上期减少0.16%
海特生物：公司埃普奈明目前销售顺利，已基本实现满产满销状态
证券之星 · 06-24
海特生物：公司埃普奈明目前销售顺利，已基本实现满产满销状态
海特生物(300683)6月10日股东户数1.72万户，较上期减少3.28%
证券之星 · 06-12
海特生物(300683)6月10日股东户数1.72万户，较上期减少3.28%
海特生物：截止6月10日，公司股东人数为17,207户
证券之星 · 06-12
海特生物：截止6月10日，公司股东人数为17,207户
海特生物：公司目前埃普奈明产能约为35万支/年
证券之星 · 06-11
海特生物：公司目前埃普奈明产能约为35万支/年
海特生物(300683)5月29日股东户数1.78万户，较上期减少0.12%
证券之星 · 06-02
海特生物(300683)5月29日股东户数1.78万户，较上期减少0.12%
海特生物：截止5月29日,公司股东人数为17,790户
证券之星 · 06-02
海特生物：截止5月29日,公司股东人数为17,790户
海特生物：埃普奈明针对软骨肉瘤的新适应症已申报正式注册临床
证券之星 · 06-02
海特生物：埃普奈明针对软骨肉瘤的新适应症已申报正式注册临床
股市必读：海特生物(300683)股东户数1.78万户，较上期减少5.8%
证券之星 · 05-27
股市必读：海特生物(300683)股东户数1.78万户，较上期减少5.8%
海特生物：截止5月20日，公司股东人数为17,811户
证券之星 · 05-26
海特生物：截止5月20日，公司股东人数为17,811户
股市必读：海特生物(300683)股东户数1.78万户，较上期减少5.8%
证券之星 · 05-26
股市必读：海特生物(300683)股东户数1.78万户，较上期减少5.8%
加载更多
公司概况
公司名称：
武汉海特生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-08-08
主营业务：
武汉海特生物制药股份有限公司的主营业务是大分子生物药、小分子化学药、原料药与医药中间体的生产销售，同时也为国内外的制药企业提供制剂和原料药的CRO、CMO和CDMO技术服务。公司的主要产品是技术服务、注射用鼠神经生长因子、注射用埃普奈明。
发行价格：
32.94
{"stockData":{"symbol":"300683","market":"SZ","secType":"STK","nameCN":"海特生物","latestPrice":25.6,"timestamp":1784876622000,"preClose":27.34,"halted":0,"volume":6739998,"delay":0,"changeRate":-0.0636,"floatShares":122000000,"shares":131000000,"eps":-1.8365,"marketStatus":"已收盘","change":-1.74,"latestTime":"07-24 15:00:00","open":26.96,"high":27.34,"low":25.6,"amount":178000000,"amplitude":0.0636,"askPrice":25.62,"askSize":4,"bidPrice":25.6,"bidSize":139,"shortable":0,"etf":0,"ttmEps":-1.8365,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"adjPreClose":27.34,"symbolType":"stock","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":30.07,"lowLimit":24.61,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":130894391,"isCdr":false,"pbRate":1.67,"roa":"--","roe":"--","epsLYR":-1.77,"committee":-0.010274,"marketValue":3351000000,"turnoverRate":0.0552,"status":1,"floatMarketCap":3125000000},"requestUrl":"/m/hq/s/300683","defaultTab":"news","newsList":[{"id":"2653405700","title":"海特生物最新公告：注射用埃普奈明临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2653405700","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653405700?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:54","pubTimestamp":1784883291,"startTime":"0","endTime":"0","summary":"海特生物(300683.SZ)公告称，公司申报的注射用埃普奈明(商品名：沙艾特)用于不可切除或转移的经典型软骨肉瘤适应症的临床试验申请获得国家药监局受理。该药品为公司自主研发的国家I类重组蛋白类创新药，是全球首个且唯一上市的死亡受体4/死亡受体5激动剂。目前，尚无针对软骨肉瘤适应症的药物获批上市，该药品研发周期长、风险较高，短期内对公司业绩不会产生实际影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400029063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651453630","title":"海特生物：推进埃普奈明新产能扩建及新适应症拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2651453630","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651453630?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:21","pubTimestamp":1784103670,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物07月15日在投资者关系平台上答复投资者关心的问题。请问除了扩产，实体瘤拓展和MM一二线推进两者中，公司有无优先级海特生物回复：您好，感谢您对公司的关注。公司今年重点工作是推进埃普奈明新产能的扩建及新适应症的拓展。埃普奈明针对软骨肉瘤的新适应症研究，已申报正式注册临床，目前正在Pre-IND阶段，预计今年将开展正式临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650990174","title":"股市必读：海特生物(300683)股东户数1.77万户，较上期增加2.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650990174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650990174?lang=zh_cn&edition=full","pubTime":"2026-07-09 01:12","pubTimestamp":1783530731,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，海特生物报收于24.79元，下跌4.29%，换手率5.2%，成交量6.35万手，成交额1.61亿元。交易信息汇总资金流向7月8日主力资金净流出1379.64万元；游资资金净流出714.95万元；散户资金净流入2094.59万元。股本股东变化股东户数变动截至2026年6月30日，公司股东户数为1.77万户，较6月18日增加511.0户，增幅2.97%；户均持股数量由7619.0股减少至7399.0股，户均持股市值为18.5万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649420956","title":"海特生物：埃普奈明的新建设计产能为120万支","url":"https://stock-news.laohu8.com/highlight/detail?id=2649420956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649420956?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:57","pubTimestamp":1783472229,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：关于CPT新增产能，5月14日公布是新产能是120万支，而最近的回答又是100万支，两次回答的数据不一致，请问是什么原因？？请认真回答，别敷衍，谢谢海特生物回复：您好，感谢您对公司的关注。埃普奈明的新建设计产能为120万支，目前项目正在推进过程中，新增产能预计明年下半年可以实现。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800008732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995642","title":"海特生物：截止6月30日，公司股东人数为17,691户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995642","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649995642?lang=zh_cn&edition=full","pubTime":"2026-07-08 08:54","pubTimestamp":1783472050,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物07月07日在投资者关系平台上答复投资者关心的问题。已有部分代谢类中间体完成交付，目前相关业务收入占公司合并报表的营收比例较小。另外，二级市场股价受多重因素影响，股票价格短期内存在波动。截止6月30日，公司股东人数为17,691户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800008540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649732496","title":"股市必读：海特生物(300683)股东户数1.77万户，较上期增加2.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649732496","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649732496?lang=zh_cn&edition=full","pubTime":"2026-07-07 01:00","pubTimestamp":1783357236,"startTime":"0","endTime":"0","summary":"截至2026年7月6日收盘，海特生物报收于27.52元，下跌0.22%，换手率10.84%，成交量13.23万手，成交额3.74亿元。股本股东变化：截至2026年6月30日，公司股东户数为1.77万户，较6月18日增加511户，增幅2.97%。股本股东变化股东户数变动截至2026年6月30日公司股东户数为1.77万户，较6月18日增加511.0户，增幅为2.97%；户均持股数量由上期的7619.0股减少至7399.0股，户均持股市值为18.5万元。截止6月30日，公司股东人数为17,691户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700000529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649891642","title":"海特生物：截止6月30日，公司股东人数为17,691户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649891642","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649891642?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:24","pubTimestamp":1783326252,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)07月06日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问公司6月底的股东人数是多少？谢谢海特生物回复：您好，感谢您对公司的关注！截止6月30日，公司股东人数为17,691户。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600021511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685708","title":"海特生物（300683）披露将参加2026年湖北辖区投资者集体接待日暨2025年度业绩说明会，7月02日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685708","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648685708?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:32","pubTimestamp":1783002739,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，海特生物报收于26.78元，较前一交易日上涨0.11%，最新总市值为35.05亿元。该股当日开盘26.77元，最高27.58元，最低26.1元，成交额达2.58亿元，换手率为7.86%。海特生物于近日披露《关于参加湖北辖区上市公司2026年投资者集体接待日活动暨2025年度业绩说明会的公告》。投资者可通过“全景路演”网站、全景财经微信公众号或全景路演APP参与；公司高管将就2025年度业绩、公司治理、发展战略、经营状况等问题与投资者进行在线交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646103820","title":"海特生物：注射用硫酸艾沙康唑是公司今年刚获批的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2646103820","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646103820?lang=zh_cn&edition=full","pubTime":"2026-06-25 15:42","pubTimestamp":1782373329,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)06月25日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问贵司注射用硫酸艾沙康唑今年下半年会有产出吗？能产生收入多少？该药品何时达产，达产产能是多少支/年。谢谢海特生物回复：您好，感谢您对公司的关注。注射用硫酸艾沙康唑是公司今年刚获批的产品，目前公司正在积极准备该产品的集采工作，预计今年下半年不会产生较大的收入。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500023601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645899499","title":"海特生物(300683)6月18日股东户数1.72万户，较上期减少0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645899499","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645899499?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:40","pubTimestamp":1782294054,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海特生物披露，截至2026年6月18日公司股东户数为1.72万户，较6月10日减少27.0户，减幅为0.16%。在医疗服务行业个股中，海特生物股东户数低于行业平均水平，截至6月18日，医疗服务行业平均股东户数为4.82万户。从股价来看，2026年6月10日至2026年6月18日，海特生物区间跌幅为1.62%，在此期间股东户数减少27.0户，减幅为0.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400032723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645189856","title":"海特生物：公司埃普奈明目前销售顺利，已基本实现满产满销状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2645189856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645189856?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:37","pubTimestamp":1782286649,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)06月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请告知2026年贵司1~5月各个单月的艾普奈明的生产销售支数。致谢！海特生物回复：感谢您对公司的关注。公司埃普奈明目前销售顺利，已基本实现满产满销状态，符合公司的预期，具体销售情况请关注公司的定期报告。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400023087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642618742","title":"海特生物(300683)6月10日股东户数1.72万户，较上期减少3.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642618742","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642618742?lang=zh_cn&edition=full","pubTime":"2026-06-12 17:35","pubTimestamp":1781256915,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海特生物披露，截至2026年6月10日公司股东户数为1.72万户，较5月29日减少583.0户，减幅为3.28%。在医疗服务行业个股中，海特生物股东户数低于行业平均水平，截至6月10日，医疗服务行业平均股东户数为4.82万户。从股价来看，2026年5月29日至2026年6月10日，海特生物区间跌幅为10.47%，在此期间股东户数减少583.0户，减幅为3.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200027675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642592265","title":"海特生物：截止6月10日，公司股东人数为17,207户","url":"https://stock-news.laohu8.com/highlight/detail?id=2642592265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642592265?lang=zh_cn&edition=full","pubTime":"2026-06-12 16:27","pubTimestamp":1781252832,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)06月12日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问公司6月10日的股东人数是多少？谢谢！海特生物回复：尊敬的投资者，您好！截止6月10日，公司股东人数为17,207户，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200025310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642403962","title":"海特生物：公司目前埃普奈明产能约为35万支/年","url":"https://stock-news.laohu8.com/highlight/detail?id=2642403962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642403962?lang=zh_cn&edition=full","pubTime":"2026-06-11 11:33","pubTimestamp":1781148829,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物06月10日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：关于公司埃普奈明产能，自2024年，2025年直到2026年4月投资者交流，路演，环评，新浪财经报道中，公司官方口径以及一直都是35万只/年。但同月末的2026年4月29日的业绩说明会中，变为产线满负荷约100万只/年，基本满产满销。公司目前埃普奈明产能约为35万支/年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100014772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640919085","title":"海特生物(300683)5月29日股东户数1.78万户，较上期减少0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640919085","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640919085?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:37","pubTimestamp":1780393038,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海特生物披露，截至2026年5月29日公司股东户数为1.78万户，较5月20日减少21.0户，减幅为0.12%。户均持股数量由上期的7349.0股增加至7358.0股，户均持股市值为20.23万元。在医疗服务行业个股中，海特生物股东户数低于行业平均水平，截至5月29日，医疗服务行业平均股东户数为4.86万户。根据统计，海特生物2026年5月20日至2026年5月29日，主力资金净流出6908.79万元，游资资金净流出1662.18万元，散户资金净流入8570.97万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640425913","title":"海特生物：截止5月29日,公司股东人数为17,790户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640425913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640425913?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:57","pubTimestamp":1780387026,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问公司5月底的股东人数是多少？谢谢！海特生物回复：感谢您对公司的关注。截止5月29日,公司股东人数为17,790户，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200026910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640374913","title":"海特生物：埃普奈明针对软骨肉瘤的新适应症已申报正式注册临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2640374913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640374913?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:45","pubTimestamp":1780386319,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物06月02日在投资者关系平台上答复投资者关心的问题。期待海特真正飞跃。埃普奈明针对软骨肉瘤的新适应症已申报正式注册临床，目前正在Pre-IND阶段，预计今年将开展正式临床试验；ASCO年会壁报分享了软骨肉瘤的21人的临床数据，大样本数据要等正式临床开展后才会出来。公司与苏州朗睿的合作持续进行中，项目进展顺利，未来有重大进展我们会及时披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200025101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300683"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638429544","title":"股市必读：海特生物(300683)股东户数1.78万户，较上期减少5.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638429544","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638429544?lang=zh_cn&edition=full","pubTime":"2026-05-27 02:16","pubTimestamp":1779819382,"startTime":"0","endTime":"0","summary":"截至2026年5月26日收盘，海特生物报收于29.46元，下跌2.09%，换手率4.01%，成交量4.9万手，成交额1.44亿元。来自股本股东变化：截至5月20日股东户数环比减少5.8%，户均持股上升至7349股，筹码集中度提升。股本股东变化股东户数变动近日海特生物披露，截至2026年5月20日公司股东户数为1.78万户，较5月8日减少1097.0户，减幅为5.8%。户均持股数量由上期的6923.0股增加至7349.0股，户均持股市值为25.03万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700001900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669505","title":"海特生物：截止5月20日，公司股东人数为17,811户","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638669505?lang=zh_cn&edition=full","pubTime":"2026-05-26 08:48","pubTimestamp":1779756492,"startTime":"0","endTime":"0","summary":"证券之星消息，海特生物(300683)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司最新股东人数是多少？海特生物回复：尊敬的投资者，您好！截止5月20日，公司股东人数为17,811户。谢谢。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600006242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638551612","title":"股市必读：海特生物(300683)股东户数1.78万户，较上期减少5.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638551612","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638551612?lang=zh_cn&edition=full","pubTime":"2026-05-26 01:05","pubTimestamp":1779728712,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，海特生物报收于30.09元，下跌5.14%，换手率6.11%，成交量7.45万手，成交额2.28亿元。来自股本股东变化：截至5月20日股东户数环比下降5.8%，户均持股上升至7349股，筹码集中度提升。股本股东变化股东户数变动近日海特生物披露，截至2026年5月20日公司股东户数为1.78万户，较5月8日减少1097.0户，减幅为5.8%。户均持股数量由上期的6923.0股增加至7349.0股，户均持股市值为25.03万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600000937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300683","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785050861973,"stockEarnings":[{"period":"1week","weight":-0.049},{"period":"1month","weight":0.0428},{"period":"3month","weight":-0.2205},{"period":"6month","weight":-0.2315},{"period":"1year","weight":-0.3991},{"period":"ytd","weight":-0.0768}],"compareEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":-0.0722},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.0778},{"period":"1year","weight":0.0578},{"period":"ytd","weight":-0.039}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉海特生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17691人(较上一季度增加2.97%)","perCapita":"6899股","listingDate":"2017-08-08","address":"湖北省武汉市蔡甸区经济技术开发区海特科技园","registeredCapital":"13089万元","survey":" 武汉海特生物制药股份有限公司的主营业务是大分子生物药、小分子化学药、原料药与医药中间体的生产销售，同时也为国内外的制药企业提供制剂和原料药的CRO、CMO和CDMO技术服务。公司的主要产品是技术服务、注射用鼠神经生长因子、注射用埃普奈明。","listedPrice":32.94},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海特生物(300683)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海特生物,300683,海特生物股票,海特生物股票老虎,海特生物股票老虎国际,海特生物行情,海特生物股票行情,海特生物股价,海特生物股市,海特生物股票价格,海特生物股票交易,海特生物股票购买,海特生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海特生物(300683)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海特生物(300683)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}